Kyriaki Cholidou

Dr. Kyriaki Cholidou

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2013 in Sleep and Breathing
Verified
Journal Article
Closed access
PDF file
CDC. Diamanti
C. Diamanti
EMEffrosyni Manali
Effrosyni Manali
MGM. Ginieri-Coccossis
M. Ginieri-Coccossis
KVKonstantinos N Vougas
Konstantinos N Vougas
KCKyriaki Cholidou
Kyriaki Cholidou
MAM. Alchanatis
M. Alchanatis

17 August 2012 in Digestive Diseases and Sciences
Verified
Journal Article
Closed access
PDF file
IKIoannis D. Kostakis
Ioannis D. Kostakis
KCKyriaki Cholidou
Kyriaki Cholidou
AVAristeidis Vaiopoulos
Aristeidis Vaiopoulos
IVIoannis Vlachos
Ioannis Vlachos
DPDespina Perrea
Despina Perrea
NVNatalia Vaou
Natalia Vaou

1 March 2013 in Cytokine
Verified
Journal Article
Closed access
KCKyriaki Cholidou
Kyriaki Cholidou
IKIoannis D. Kostakis
Ioannis D. Kostakis
EMEffrosyni D. Manali
Effrosyni D. Manali
DPDespina Perrea
Despina Perrea
AMAlexandra Margeli
Alexandra Margeli
MAManos Alchanatis
Manos Alchanatis

13 May 2014 in Clinical Research in Cardiology
Verified
Journal Article
Closed access
PDF file
KCKyriaki Cholidou
Kyriaki Cholidou
EMEffrosyni D. Manali
Effrosyni D. Manali
FKFotis Kapsimalis
Fotis Kapsimalis
IKIoannis D. Kostakis
Ioannis D. Kostakis
KVKonstantinos N Vougas
Konstantinos N Vougas
MAManos Alchanatis
Manos Alchanatis

18 December 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MAMaria Anastasiou
Maria Anastasiou
EVANGELOS OIKONOMOUEVANGELOS OIKONOMOU
EVANGELOS OIKONOMOU
PTPanagiotis Theofilis
Panagiotis Theofilis
Maria GazouliMaria Gazouli
Maria Gazouli
GPGeorge-Angelos Papamikroulis
George-Angelos Papamikroulis
Dimitris TousoulisDimitris Tousoulis
Dimitris Tousoulis
Background: HER2-positive breast cancer patients receiving chemotherapy and targeted therapy (including anthracyclines and trastuzumab) face an elevated risk of cardiotoxicity, which can lead to long-term cardiovascular complications. Identifying predictive biomarkers is essential for early intervention. Circulating microRNAs (miRNAs), known regulators of gene expression and cardiovascular function, have emerged as potential indicators of cardiotoxicity. This study aims to evaluate the differential expression of circulating miRNAs in HER2-positive breast cancer patients undergoing chemotherapy and to assess their prognostic ability for therapy-induced cardiotoxicity using machine learning models. Methods: Forty-seven patients were assessed for cardiac toxicity at baseline and every 3 months, up to 15 months. Blood samples were collected at baseline. MiRNA expression profiling for 84 microRNAs was performed using the miRCURY LNA miRNA PCR Panel. Differential expression was calculated via the 2−∆∆Ct method. The five most upregulated and five most downregulated miRNAs were further assessed using univariate logistic regression and receiver operating characteristic (ROC) analysis. Five machine learning models (Decision Tree, Random Forest (RF), Support Vector Machine (SVM), Gradient Boosting Machine (GBM), k-Nearest Neighbors (KNN)) were developed to classify cardiotoxicity based on miRNA expression. Results: Forty-five miRNAs showed significant differential expression between cardiac toxic and non-toxic groups. ROC analysis identified hsa-miR-155-5p (AUC 0.76, p = 0.006) and hsa-miR-124-3p (AUC 0.75, p = 0.007) as the strongest predictors. kNN, SVM, and RF models demonstrated high prognostic accuracy. The decision tree model identified hsa-miR-17-5p and hsa-miR-185-5p as key classifiers. SVM and RF highlighted additional miRNAs associated with cardiotoxicity (SVM: hsa-miR-143-3p, hsa-miR-133b, hsa-miR-145-5p, hsa-miR-185-5p, hsa-miR-199a-5p, RF: hsa-miR-185-5p, hsa-miR-145-5p, hsa-miR-17-5p, hsa-miR-144-3p, and hsa-miR-133a-3p). Performance metrics revealed that SVM, kNN, and RF models outperformed the decision tree in overall prognostic accuracy. Pathway enrichment analysis of top-ranked miRNAs demonstrated significant involvement in apoptosis, p53, MAPK, and focal adhesion pathways, all known to be implicated in chemotherapy-induced cardiac stress and remodeling. Conclusions: Circulating miRNAs show promise as biomarkers for predicting cardiotoxicity in breast cancer patients. Machine learning approaches may enhance miRNA-based risk stratification, enabling personalized monitoring and early cardioprotective interventions.

24 January 2013
Verified
Journal Article
Closed access
IKIoannis D Kostakis
Ioannis D Kostakis
NTNikolaos G Tsoukalas
Nikolaos G Tsoukalas
DADionysios C Aravantinos
Dionysios C Aravantinos
IGIlias G Gkizis
Ilias G Gkizis
KCKyriaki Cholidou
Kyriaki Cholidou
DPDimitris P Papadopoulos
Dimitris P Papadopoulos